This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)

< Back

Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)


Respiratory Disease and Thoracic Surgery

November 2017

Benralizumab is a new drug being developed for the treatment of chronic obstructive pulmonary disease. It is administered by injection under the skin and acts by targeting specific proteins that
causes the airway to narrow. If benralizumab is licensed for use in the UK, it could be a new treatment option for patients with chronic obstructive pulmonary disease that may improve quality of life and reduce the number of exacerbations.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Benralizumab for COPD


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts